会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 73. 发明授权
    • 항동맥경화 활성을 나타내는 틸리아닌
    • 항동맥경화활성을나타내틸리아닌
    • KR100454087B1
    • 2004-11-02
    • KR1020010039575
    • 2001-07-03
    • 한국생명공학연구원
    • 이형규오세량안경섭최순자김정희오구택홍정주남궁우
    • A61K31/7048
    • PURPOSE: Provided is tilianin for anti-inflammatory activity and anti-atherogenic activity, which inhibits expression of intercellular adhesion molecule-1(ICAM-1) and vascular cell adhesion molecule-1(VCAM-1) and reduces progression of arteriosclerosis diseases. Therefore, it is useful for the prevention and treatment of cardiovascular diseases. CONSTITUTION: Tilianin is a synthetic chemical compound or isolated from Prunella vulgaris var. lilacina. It characteristically inhibits intercellular adhesion molecule-1(ICAM-1) and vascular cell adhesion molecule-1(VCAM-1), and is represented by the formula(1). The anti-inflammatory and anti-atherogenic agents contains the tilianin as an active ingredient.
    • 目的:本发明提供了用于抑制细胞间粘附分子-1(ICAM-1)和血管细胞粘附分子-1(VCAM-1)表达的抗炎活性和抗动脉粥样硬化活性,并减少动脉硬化疾病进展的倾斜蛋白。 因此,它对心血管疾病的预防和治疗很有用。 构成:Tilianin是一种合成化合物或从夏枯草var。 lilacina。 它特征性地抑制细胞间粘附分子-1(ICAM-1)和血管细胞粘附分子-1(VCAM-1),并由式(1)表示。 抗炎和抗动脉粥样硬化剂含有tilianin作为活性成分。
    • 74. 发明公开
    • 세포사멸 유도작용을 갖는 락톤 화합물
    • LACTONE化合物诱导凋亡
    • KR1020040003114A
    • 2004-01-13
    • KR1020020035558
    • 2002-06-25
    • 한국생명공학연구원
    • 이형규권옥경안경섭민병선김미란김정희
    • A61K31/365A61P5/00
    • PURPOSE: Provided is a lactone compound obtained from Actinodaphne lancifolia. The compound has apoptosis activity and less toxicity, and is thus useful as therapeutic agents or aids for chronic or incurable diseases including immune system disease and brain disease. CONSTITUTION: A method for obtaining a lactone compound comprises the steps of: extracting pulverized Actinodaphne lancifolia with a mixture of methanol and water; fractionating with hexane and ethylacetate to give hexane and ethylacetate fractions; subjecting the hexane fraction to absorption chromatography; and obtaining isolancifolide, lancifolide and actinolide B of the formula(1-3) from the hexane-ethylacetate fraction.
    • 目的:提供从Actinodaphne lancifolia获得的内酯化合物。 该化合物具有凋亡活性和较低的毒性,因此可用作治疗剂或用于慢性或不治之症(包括免疫系统疾病和脑部疾病)的辅助剂。 构成:获得内酯化合物的方法包括以下步骤:用甲醇和水的混合物提取粉碎的放线菌素; 用己烷和乙酸乙酯分馏,得到己烷和乙酸乙酯级分; 使己烷部分进行吸收色谱; 并从己烷 - 乙酸乙酯部分中获得式(1-3)的间苯三酚,兰可夫酸和锕系元素B。
    • 75. 发明公开
    • 항염증 활성 및 항동맥경화 활성을 나타내는 배초향 추출물
    • AGASTACHE RUGOSA提取物展示抗炎活性和抗炎活性
    • KR1020020070062A
    • 2002-09-05
    • KR1020010039574
    • 2001-07-03
    • 한국생명공학연구원
    • 이형규오세량안경섭최순자김정희오구택홍정주박성규
    • A61K36/532A61P29/00A61P9/10
    • A61K36/532A23L33/105A23L33/11
    • PURPOSE: Provided is a pharmaceutical composition containing an Agastache rugosa extract and a solvent fraction thereof as an effective component which exhibits anti-inflammatory activity and antiatherosclerotic activity and is useful as medicaments or food additives for the prevention and treatment of inflammatory diseases, arteriosclerosis related with inflammatory reaction and circulatory organ-related diseases caused thereby. CONSTITUTION: The attachment pharmaceutical composition contains an Agastache rugosa extract and a solvent fraction obtained by fractioning the extract with hexane. Chloroform or butanol inhibits the activity of a complement system as an inflammatory reactive factor and has an excellent activity on the inhibition of expression of intercellular adhesion molecule-1 and formation of nitric oxide.
    • 目的:提供含有藿香粗提物及其溶剂馏分作为有效成分的药物组合物,其具有抗炎活性和抗动脉粥样硬化活性,并且可用作预防和治疗炎性疾病,与动脉硬化相关的动脉硬化的药物或食品添加剂 由此引起炎症反应和循环器官相关疾病。 构成:附着药物组合物含有藿香提取物和通过用己烷分离萃取物而获得的溶剂级分。 氯仿或丁醇抑制补体系统作为炎性反应因子的活性,对抑制细胞间粘附分子-1的表达和一氧化氮的形成具有优异的活性。